Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on November 24, with *ST Lvkang leading the drop [1][2] Market Performance - The Shanghai Composite Index closed at 3836.77, up 0.05% - The Shenzhen Component Index closed at 12585.08, up 0.37% [1] Individual Stock Performance - Notable gainers in the animal health sector included: - Shenlian Biological (688098) with a closing price of 9.57, up 2.57% on a trading volume of 55,100 shares and a turnover of 52.32 million yuan - Yongshun Biological (920729) at 8.95, up 1.59% with a trading volume of 15,900 shares and a turnover of 14.22 million yuan - Xianfeng Holdings (002141) at 3.98, up 1.53% with a trading volume of 694,200 shares and a turnover of 275 million yuan [1] Capital Flow Analysis - The animal health sector saw a net outflow of 35.49 million yuan from institutional investors, while retail investors contributed a net inflow of 31.36 million yuan [2][3] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [3] Stock-Specific Capital Flow - Key stocks with significant capital flow include: - Dayu Biological (920970) with a net inflow of 1.55 million yuan from institutional investors - Pulaike (603566) with a net inflow of 0.99 million yuan from institutional investors - Shenlian Biological (688098) faced a net outflow of 2.88 million yuan from institutional investors [3]

证券代码：920970 证券简称：大禹生物 公告编号：2025-134 山西大禹生物工程股份有限公司 库存股注销完成暨股份变动公告 公司于 2022 年 11 月 21 日完成本次股份回购，通过回购股份专用证券账户，以连 续竞价转让方式累计回购股份数量 559,600 股，占公司总股本 1.00%，占预计回购总数 量上限的 100.00%，最高成交价为 9.57 元/股，最低成交价为 8.91 元/股，已支付的总金 额为 5,105,602.57 元（不含印花税、佣金等交易费用），占公司拟回购资金总额上限的 91.2366%。具体内容详见公司于 2022 年 11 月 22 日在北京证券交易所信息披露平台 （http://www.bse.cn/）披露的《回购股份结果公告》（公告编号：2022-089）。 公司于 2025 年 10 月 9 日召开第四届董事会第六次会议、2025 年 10 月 28 日召开 2025 年第四次临时股东会，审议通过了《关于变更回购股份用途并注销暨减少注册资 本的议案》。根据《中华人民共和国公司法》、《北京证券交易所上市公司持续监管指引 第 4 号——股份回购》的有关规定，公司拟将 ...

Core Viewpoint - The animal health sector experienced a significant decline of 4.0% on November 21, with Shunlian Biological leading the drop [1] Market Performance - The Shanghai Composite Index closed at 3834.89, down 2.45% - The Shenzhen Component Index closed at 12538.07, down 3.41% [1] Individual Stock Performance - Shunlian Biological (688098) closed at 9.33, down 5.85% with a trading volume of 58,100 shares and a turnover of 55.30 million yuan - Huisheng Biological (300871) closed at 19.33, down 5.71% with a trading volume of 65,400 shares and a turnover of 130 million yuan - Yongshun Biological (920729) closed at 8.81, down 5.47% with a trading volume of 23,700 shares and a turnover of 21.71 million yuan - *ST Green Health (002868) closed at 41.88, down 4.99% with a trading volume of 5,569 shares and a turnover of 23.32 million yuan - Biological Shares (600201) closed at 11.76, down 4.85% with a trading volume of 491,800 shares [1] Capital Flow Analysis - The animal health sector saw a net outflow of 128 million yuan from institutional investors, while retail investors had a net inflow of 87.82 million yuan [1] - The following stocks had notable capital flows: - Shunlian Biological: net outflow of 11.71 million yuan from institutional investors [2] - *ST Green Health: net outflow of 6.34 million yuan from institutional investors, but a net inflow of 990,000 yuan from retail investors [2] - Huisheng Biological: net outflow of 8.69 million yuan from institutional investors, with a net inflow of 432,630 yuan from retail investors [2]

Core Insights - The animal health sector experienced a decline of 0.24% on November 17, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.68, up 5.12% [1] - *ST Lvkang (code: 002868) with a closing price of 42.57, up 5.01% [1] - Houfeng Holdings (code: 002141) with a closing price of 3.91, up 2.62% [1] - Major decliners included: - Dayu Biological (code: 920970) with a closing price of 8.70, down 3.87% [2] - Ruipu Biological (code: 300119) with a closing price of 20.61, down 2.92% [2] - Zhongmu Co., Ltd. (code: 600195) with a closing price of 7.94, down 1.98% [2] Capital Flow - The animal health sector saw a net outflow of 10.15 million yuan from institutional investors, while retail investors experienced a net outflow of 20.76 million yuan [2] - Conversely, speculative funds recorded a net inflow of 30.91 million yuan [2] Individual Stock Capital Flow - Notable capital flows included: - Biological Shares (code: 600201) with a net inflow of 12.08 million yuan from institutional investors [3] - Xianfeng Holdings (code: 002141) with a net inflow of 9.50 million yuan from institutional investors [3] - Ruipu Biological (code: 300119) with a net inflow of 1.05 million yuan from speculative funds [3] - Decliners in capital flow included: - *ST Lvkang (code: 002868) with a net outflow of 0.79 million yuan from institutional investors [3] - Hai Li Biological (code: 603718) with a net outflow of 2.82 million yuan from institutional investors [3]

山西大禹生物工程股份有限公司 公司章程 二〇二五年十一月 1 | 第二节 | 解散和清算 | 50 | | --- | --- | --- | | 第十章 | 修改章程 | 52 | | 第十一章 | 附则 | 52 | 第一章 总则 第一条 为维护山西大禹生物工程股份有限公司（以下简称"公司"）、股东、 职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 和其他有关规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司系由山西大禹生物工程有限公司整体变更设立的股份有限公司，在运城市 市场监督管理局注册登记，取得企业法人营业执照，统一社会信用代码 911408003 96698854U。 第三条 公司经北京证券交易所审核并于 2022 年 4 月 19 日经中国证券监督管 理委员会（以下简称"中国证监会"）作出同意注册的决定，向不特定合格投资者 发行人民币普通股 1,500 万股，于 2022 年 5 月 18 日在北京证券交易所上市。 | | | | 第一章 | 总则 | ...

上海市锦天城律师事务所 关于山西大禹生物工程股份有限公司 2025 年第五次临时股东会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：（86）21-20511000 传真：（86）21-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于山西大禹生物工程股份有限公司 2025 年第五次临时股东会的法律意见书 致：山西大禹生物工程股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受山西大禹生物工程股份 有限公司（以下简称"公司"）委托，就公司召开 2025 年第五次临时股东会（以 下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《上市公司股东会规则》等法律法规和其他规范性文件以 及《山西大禹生物工程股份有限公司公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则》等规定，严格履行了法定职 责，遵循了勤勉尽责和诚实信用原则，对本次股东会所涉 ...

证券代码：920970 证券简称：大禹生物 公告编号：2025-131 山西大禹生物工程股份有限公司 2025 年第五次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 4.会议召集人：董事会 5.会议主持人：董事长闫和平先生 6.召开情况合法合规的说明： 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 11 月 13 日 2.会议召开地点：大禹生物三楼会议室 3.会议召开方式：现场投票和网络投票相结合方式 2.回避表决情况 该议案不涉及关联交易，无需回避表决。 三、律师见证情况 本次股东会会议的召集、召开、议案审议程序符合有关法律、行政法规、部 门规章、规范性文件和《公司章程》的相关规定。 （二）会议出席情况 出席和授权出席本次股东会的股东共 15 人，持有表决权的股份总数 57,922,037 股，占公司有表决权股份总数的 52.2758%。 其中通过网络投票参与本次股东会的股东共 3 人，持有表决权的股份总数 1,123,036 股，占公司有表决权股份 ...

Core Insights - The animal health sector experienced a slight increase of 0.36% on November 6, with *ST Lvkang leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Stock Performance - *ST Lvkang (002868) closed at 30.25, with a rise of 5.00% and a trading volume of 32,200 hands, amounting to a transaction value of 96.94 million yuan [1] - Other notable stocks include: - KQ Bio (688526) at 16.07, up 0.69% [1] - Biological Shares (600201) at 10.35, up 0.68% with a transaction value of 153 million yuan [1] - Ruipu Biological (300119) at 20.46, up 0.20% [1] - Pulaike (603566) at 14.09, up 0.14% [1] Capital Flow - The animal health sector saw a net outflow of 17.47 million yuan from institutional investors, while retail investors contributed a net inflow of 8.89 million yuan [2] - The capital flow for individual stocks indicates: - *ST Lvkang had a net inflow of 7.56 million yuan from institutional investors [3] - KQ Bio experienced a net inflow of 4.84 million yuan [3] - Biological Shares had a net inflow of 2.64 million yuan [3]

Market Overview - The animal health sector experienced a decline of 2.79% on October 30, with Jinhe Biology leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Individual Stock Performance - Jinhe Biology (002688) closed at 6.25, down 7.13% with a trading volume of 578,000 shares and a transaction value of 367 million yuan [1] - Keqian Biology (688526) closed at 16.15, down 6.76% with a trading volume of 139,800 shares and a transaction value of 228 million yuan [1] - Maofeng Holdings (002141) closed at 3.92, down 5.08% with a trading volume of 461,300 shares and a transaction value of 18.3 million yuan [1] - Other notable declines include Dayu Biology (920970) down 2.69%, and Pulaike (603566) down 2.68% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 84.7 million yuan from institutional investors, while retail investors experienced a net outflow of 16.5 million yuan [1] - Speculative funds recorded a net inflow of 101 million yuan [1] Detailed Capital Flow for Selected Stocks - Keqian Biology (688526) had a net inflow of 39.6 million yuan from institutional investors, while retail investors saw a net outflow of 60.9 million yuan [2] - Huisheng Biology (300871) experienced a net inflow of 18.3 million yuan from institutional investors, with a net outflow of 21.2 million yuan from retail investors [2] - Other stocks like Pulaike (603566) and Maofeng Holdings (002141) also reported significant net outflows from institutional investors [2]

证券代码：920970 证券简称：大禹生物 公告编号：2025-130 山西大禹生物工程股份有限公司（以下简称"公司"）于2025年10月9日召开了 第四届董事会第六次会议，审议通过了《关于变更回购股份用途并注销暨减少注 册资本的议案》、《关于拟减少公司注册资本并修订<公司章程>的议案》，上述议 案已于2025年10月28日经公司2025年第四次临时股东会审议通过。 根据《北京证券交易所股票上市规则》《北京证券交易所上市公司持续监 管指引第4号——股份回购》等相关规定，对于回购股份用于股权激励或员工 持股计划的，应当在公司发布回购结果公告后三年内转让或者注销。 鉴于上述三年期限即将届满，结合公司实际情况，公司拟对回购专用证券 账户中持有的559,600股股份予以注销。注销完成后，公司注册资本将由 111,360,400股变更为110,800,800股。 山西大禹生物工程股份有限公司 关于减少注册资本通知债权人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、通知债权人的原由 二、需债权人知晓的 ...